Aspergillus infection is an infectious complication which frequently occurs in cystic
fibrosis. The efficacy of azole therapy in patients with cystic fibrosis with persistent
positive sputums for Aspergillus is still unknown. Furthermore, the efficacy of itraconazole
and voriconazole in this indication has never been evaluated in a large prospective
controlled clinical trial, even though many teams already use it. The ATCF study aims to
assess in patients with cystic fibrosis with persistent Aspergillus positive cultures the
efficacy of itraconazole and voriconazole on the negativisation of the sputum cultures for
Aspergillus.